3 hours ago
1
aluxum/E+ via Getty Images
Altimmune (NASDAQ:ALT) shares rose on Tuesday after the company reported promising Q2 results banking on its experimental candidate, pemvidutide.
Pemvidutide is in development for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, alcohol-associated liver disease and obesity.
The shares
English (US) ·